The estimated Net Worth of Edward W Holmes is at least $295 Thousand dollars as of 14 June 2024. Edward Holmes owns over 3,131 units of Arcturus Therapeutics Inc stock worth over $65,688 and over the last 5 years he sold ARCT stock worth over $0. In addition, he makes $229,747 as Independent Director at Arcturus Therapeutics Inc.
Sign up
Edward Holmes ARCT stock SEC Form 4 insiders trading
Edward has made over 1 trades of the Arcturus Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 3,131 units of ARCT stock worth $65,688 on 14 June 2024.
The largest trade he's ever made was exercising 3,131 units of Arcturus Therapeutics Inc stock on 14 June 2024 worth over $65,688. On average, Edward trades about 522 units every 0 days since 2019. As of 14 June 2024 he still owns at least 3,131 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Edward Holmes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Holmes biography
Dr. Edward W. Holmes M.D. serves as Independent Director of the Company. Dr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. Dr. Holmes became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, on the scientific advisory board of Ajinomoto and on the board of directors of Tularik , Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine. Dr. Holmes holds a Doctor of Medicine degree from the University of Pennsylvania. Dr. Holmes is nominated for re-election on our Board because of his significant experience in research, medicine and genetics.
What is the salary of Edward Holmes?
As the Independent Director of Arcturus Therapeutics Inc, the total compensation of Edward Holmes at Arcturus Therapeutics Inc is $229,747. There are 9 executives at Arcturus Therapeutics Inc getting paid more, with Andrew Sassine having the highest compensation of $1,326,880.
How old is Edward Holmes?
Edward Holmes is 79, he's been the Independent Director of Arcturus Therapeutics Inc since 2019. There are no older and 12 younger executives at Arcturus Therapeutics Inc.
What's Edward Holmes's mailing address?
Edward's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Insiders trading at Arcturus Therapeutics Inc
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch, and Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.
What does Arcturus Therapeutics Inc do?
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
What does Arcturus Therapeutics Inc's logo look like?
Complete history of Edward Holmes stock trades at Arcturus Therapeutics Inc
Arcturus Therapeutics Inc executives and stock owners
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Sassine,
Chief Financial Officer, Director -
Joseph Payne,
President, Chief Executive Officer, Director -
Joseph E. Payne M.Sc.,
Founder, Pres, CEO & Director -
Dr. Steven George Hughes M.B.A., M.D.,
Chief Medical Officer -
Dr. Padmanabh Chivukula,
Founder, Chief Scientific Officer, COO & Sec. -
Andrew H. Sassine,
CFO & Director -
Padmanabh Chivukula,
Chief Operating Officer, Chief Scientific Officer -
Lance Kurata,
Chief Legal Officer -
Karah Parschauer,
Director -
Edward Holmes,
Independent Director -
Peter Farrell,
Independent Chairman of the Board -
Magda Marquet,
Independent Director -
James Barlow,
Independent Director -
Steven Hughes,
Chief Development Officer -
Dr. Nirdosh Jagota Ph.D.,
Exec. VP & Chief Regulatory Officer -
Kevin T. Skol,
Sr. VP of Bus. Devel. & Alliance Management -
Neda Safarzadeh,
Sr. Director and Head of Investor Relations/PR & Marketing -
Dr. Dushyant B. Varshney Ph.D.,
Exec. VP & Chief Technology Officer -
Keith C. Kummerfeld CPA,
VP of Fin. & Corp. Controller -
Capital Group, Lpluxor Capi...,
-
William G Stanley,
Director -
Leslie D Michelson,
Director -
Susan E Manning,
See Remarks -
William M Kahane,
President and CEO -
Brian D Jones,
CFO and Treasurer -
Nicholas S Schorsch,
Director -
Robert Burns,
Director -
Pad Chivukula,
Chief Scientific Officer & COO -
Keith C Kummerfeld,
See Remarks -
Andy Sassine,
Chief Financial Officer -
Lance Kurata,
Chief Legal Officer -
Pharmaceutical Inc. Ultragenyx,
Director -
Jing L. Marantz,
Director -
John Markels,
Director -
Moncef Slaoui,
Director